Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405413 · ClinicalTrials.gov registry record · Phase 2
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
A Phase 2 study of Cancer, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
- 1
- Study location
NCT05405413: Recruiting Phase 2 study of Cancer, sponsored by Dartmouth-Hitchcock Medical Center.
NCT05405413 is a Phase 2 study of Cancer that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 192 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05405413, a Phase 2 study of Cancer, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-arm Phase II study to measure the impact of Molecular Tumor Board treatment recommendations on treatment decision-making in clinical practice at the Dartmouth Cancer Center. Following tumor genetic profiling, subjects will be screened for eligibility. Eligible subjects' cases will be evaluated by the Dartmouth Cancer Center Molecular Tumor Board, and treatment recommendations will be entered into the medical record as per standard procedure. The primary endpoint is a survey response from the treating physician indicating how Molecular Tumor Board evaluation impacted treatment decisions. Secondary endpoints include: 1) Molecular Tumor Board treatment recommendation; 2) disease progression on line of therapy started after MTB recommendations were made. Surveys will be administered approximately 3 and 12 months after Molecular Tumor Board recommendations are made.
Primary Outcome
Treating physicians will complete surveys at 3 months after Molecular Tumor Board recommendations are made. Survey response from the treating physician indicating how Molecular Tumor Board recommendations impacted treatment decisions.
Conditions Studied
Interventions
- OTHER Treatment recommendations made by Molecular Tumor Board.
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
What NCT05405413 shows while recruiting
NCT05405413 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Treatment recommendations made by Molecular Tumor Board. is the first listed.
NCT05405413 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05405413 about?
NCT05405413 is a clinical study titled "CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth". This is a single-arm Phase II study to measure the impact of Molecular Tumor Board treatment recommendations on treatment decision-making in clinical practice at the Dartmouth Cancer Center. Following tumor genetic profiling, subjects will be screened for eligibility. Eligible subjects' cases will b...
What is the current status of trial NCT05405413?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2024-03-19. Estimated completion is 2029-12.
What conditions does trial NCT05405413 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT05405413?
The interventions under investigation include: Treatment recommendations made by Molecular Tumor Board. (OTHER).
Who is sponsoring clinical trial NCT05405413?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05405413 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05405413's enrollment target sits among peer trials
192 239th of 615 higher than 376 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI